Thrombotic safety of rofecoxib v placebo for colorectal adenomas at 3 years*

OutcomesRofecoxibPlaceboRRI (95% CI)NNH (CI)
Event ratesPatient years at riskEvent ratesPatient years at risk
*APTC  =  Antiplatelet Trialists’ Collaboration. Other abbreviations defined in glossary; RRI, NNH, and CI calculated from relative risks in article.
Thrombotic events3.6%30592.0%332792% (19 to 211)55 (24 to 264)
APTC combined endpoint2.6%30701.4%3334106% (16 to 264)68 (28 to 447)